Status:
COMPLETED
IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney Transplantation (TASMANIA)
Lead Sponsor:
Institute for Clinical and Experimental Medicine
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18-100 years
Brief Summary
The aim of this study is to assess humoral immune response in kidney transplant recipients after SARS-CoV-2 mRNA vaccine.
Detailed Description
TASMANIA is a single-center prospective observational study with 1000 kidney transplant recipients from Institute for Clinical and Experimental Medicine (IKEM), Prague. The primary objective of the st...
Eligibility Criteria
Inclusion
- Kidney transplant recipients
- Recipient age ≥ 18 years
- Written Informed Consent and Consent for Processing Personal Data
- Vaccination with two doses of SARS-CoV-2 mRNA vaccine either before or after kidney transplantation.
Exclusion
- Active SARS-CoV-2 infection.
- Patients that received anti-SARS-CoV-2 monoclonal antibodies.
- Active infection after vaccination
- Monoclonal antibodies treatment ahead of antibody or cellular immunity screening
Key Trial Info
Start Date :
March 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2022
Estimated Enrollment :
753 Patients enrolled
Trial Details
Trial ID
NCT04832841
Start Date
March 18 2021
End Date
March 30 2022
Last Update
March 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute for Clinical and Experimental Medicine
Prague, Czechia, 140 21